FDA approves AbbVie rheumatoid arthritis drug
Reuters reported that the drug, Rinvoq, will carry a list price of $59,000 per year. AbbVie's top-selling drug, Humira, is also approved for treating RA.
Momenta’s biosimilars pullback could portend further industry exits
Expert says that biosimilars' pricing discounts and lower-than-expected patient populations could make the market less attractive for smaller players.
Why Pharma Companies Should Look To Social Media For Better Patient Insight
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.